newsfilter
← Latest News
Business Wire·

Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights

-- Positive topline clinical data from all patients in an investigator-initiated Phase 2 clinical trial evaluating stem cell mobilization and transplant engraftment using MGTA-145 plus plerixafor in patients with multiple myeloma will be presented as a